Technology Appraisals
Fully Endorsed
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA94 - Cardiovascular Disease - Statins
- This guidance has been updated and replaced by NICE CG181 - Lipid Modification, which was endorsed by the DoH in September 2014 - HSC (SQSD) (NICE CG181) 22/14
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA101 - Prostate Cancer (hormone refractory) - Docetaxel - HSS (SQSD) (NICE) 04/07
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA104 - Psoriatic Arthritis - Etanercept & Infliximab
- This guidance has been replaced by NICE TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab, which was endorsed by DoH in December 2011
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA105 - Colorectal Cancer - Laparoscopic Surgery (review) - HSS (SQSD) (NICE) 03/07
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA107 - Breast Cancer (early) Trastuzumab (Herceptin) - HSS (SQSD) (NICE) 02/07
- This guidance has been updated and replaced by NICE Clinical Guideline NG101 - Early and locally advanced breast cancer: diagnosis and management, which was endorsed by the DoH in September 2018.
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA108 - Breast Cancer (early) - Paclitaxel - HSS (SQSD) (NICE) 06/07
- This guidance has been updated and replaced by NICE Clinical Guideline NG101 - Early and locally advanced breast cancer: diagnosis and management, which was endorsed by the DoH in September 2018.
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA109 - Breast Cancer (early) - Docetaxel - HSS (SQSD) (NICE) 05/07
- This guidance has been updated and replaced by NICE Clinical Guideline NG101 - Early and locally advanced breast cancer: diagnosis and management, which was endorsed by the DoH in September 2018.